This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioReference Laboratories, Inc. Reports Sustained Growth On Strong Quarterly Results

Dr. Grodman further noted: "This past year has been tumultuous with regards to collections given the changes that have been implemented. We believe that we have been quite successful over the past few years in showing improvement in this area. The current quarter is an exception to that trend, but we believe that the exception is coming under control and we can expect to get back on track in the near term future. Since last year, we have had to deal with molecular coding changes from both Medicare and Medicaid, delays in payment related to site of service between physician office and hospital due to the end of the "grandfather" provision, as well as changes emanating from the elimination of the Blue Card program. Over the last quarter alone, there have been some delays in billing under new payer contracts while waiting for all their systems to be operational. That being said, we currently have national or subnational contracts with the five largest commercial insurers and an impressive list of participating Blue plans. We believe that the total number of lives that we cover may well rival any laboratory in the country."

Dr. Grodman continued: "Over the past quarter, the greatest increase in our DSO, almost 3 days, was by our own choice and is attributable to an issue with Horizon Blue Cross Blue Shield of New Jersey (Horizon) pursuant to which we have elected temporarily to suspend billing. Over the past several months, we have come to believe that we should have been paid for certain services rendered to Horizon under our agreement to service their PPO subscribers.  We believe Horizon has mischaracterized these services as managed care and therefore not payable under our PPO agreement. Based on Horizon's characterization of these services, we had not previously billed or recognized revenues for these services. After BioReference began to bill and was initially paid by Horizon for a fraction of these previously unbilled claims, Horizon ceased paying for these disputed services and sought to recoup those payments from monies due to us for unrelated and undisputed services rendered. As a result, we suspended billing Horizon for most services while this dispute is ongoing.  Directly and through counsel we are attempting to settle these issues; however, we are uncertain as to whether this matter will be resolved amicably or must be litigated. "

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.52 -0.19%
FB $101.68 -0.23%
GOOG $682.05 -0.16%
TSLA $147.66 -1.90%
YHOO $26.78 0.08%


Chart of I:DJI
DOW 15,876.83 +216.65 1.38%
S&P 500 1,851.03 +21.95 1.20%
NASDAQ 4,301.8840 +35.0470 0.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs